Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAxel Hauschild, Claus Garbe, Anja Gesierich et al.|BMC Cancer|2017Cited by 412
LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)Alexander Stratigos, M.G. Fury, Ketty Peris et al.|Annals of Oncology|2020Cited by 14